The Great Acquirer Strikes Again

In this video, health-care analyst David Williamson discusses Valeant's latest acquisition target. Although this is no bite-sized morsel, generic-drug maker Actavis would be a potentially transformative merger of equals. 

The deal appears to have hit a snag, and that could be the best outcome for investors in both companies. Valeant probably wouldn't offer Actavis investors much of a premium, and Valeant investors excited about small, accretive deals in the brande-drug space would be in for a rude awakening.  Watch and find out why.

What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2398923, ~/Articles/ArticleHandler.aspx, 4/20/2014 3:40:02 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement